1034183-25-9

Upstream product

• 674-82-8 4-methyleneoxetan-2-one 
• 18282-59-2 4-bromo-1,2-dichlorobenzene 

Downstream Products

• 191673-76-4 methyl 3-(3,4-dichlorophenyl)-3-butenoate 
• 191673-50-4 [(R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3,4-dichloro-phenyl)-2-hydroxy-butyl]-(2-hydroxy-ethyl)-carbamic acid tert-butyl ester 
• 191673-60-6 2-[4-t-Butoxycarbonyl-(2 R)-(3,4-dichlorophenyl)morpholin-2-yl]ethanol t-butyldimethylsilyl ether 
• 191673-32-2 (R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3,4-dichloro-phenyl)-butane-1,2-diol 
• 191673-56-0 (R)-2-(2-(3,4-dichlorophenyl)morpholin-2-yl)ethanol 
• 191673-30-0 tert-Butyl-[3-(3,4-dichloro-phenyl)-but-3-enyloxy]-dimethyl-silane 
• 272775-65-2 3-(3',4'-dichlorophenyl)-3-buten-1-ol 

Relevant academic research and scientific papers

An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin- 2-yl]ethanols, key intermediates of tachykinin receptor antagonist

We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a- d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction.